|
|||||
|
|
Human epidermal receptor 2–amplified salivary duct carcinoma: Regression with dual human epidermal receptor 2 inhibition and anti–vascular endothelial growth factor combination treatment |
|
| Authors: | Gerald S. Falchook MD Scott M. Lippman MD Christel C. Bastida PhD Razelle Kurzrock MD |
| Affiliation: | 1. Department of Investigational Cancer Therapeutics, (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas;2. Moores Cancer Center, University of California, San Diego, La Jolla, California |
| Abstract: | |
| Keywords: | salivary duct carcinoma trastuzumab lapatinib human epidermal receptor 2 (HER2) bevacizumab |